Lakefront Biotherapeutics NV (LKFT)
NasdaqGS
Price as at 1 Oct 2026, 15:15 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Lakefront Biotherapeutics NV trades at $28.88. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- David Einhorn, DME Capital Management, LP$14.47M · 0.4% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$12.23M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$8.09M · 0.0% of book
- GREENLIGHT CAPITAL INC$6.61M · 0.3% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$5.93M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own LKFT?
9 of the institutions we track reported a position in LKFT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its LKFT data?
Fundamentals for LKFT come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 15:15 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for LKFT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.